Ribo Submits European Clinical Trial Application for Phase Ⅰ Study of INHBE-Targeting siRNA RBD3133

2 SOURCES CONFIRMED · FIRST SEEN 2026-10-08 01:41 UTC · LAST UPDATE 2026-10-08 02:57 UTC

KINDNews

DIRECTION■ Unclear/unknown

SOURCES2

ENTITIES2

STORY SIZESTANDALONE

FIRST SEEN2026-10-08 01:41 UTC

LAST UPDATE2026-10-08 02:57 UTC

STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

An early-stage Phase I CTA for an siRNA candidate is years from revenue and has no listed ticker slug.

Early pipeline news, no near-term impact

CATALYST TO WATCH

Trial approval or first patient dosed

MAIN RISK

Phase I failure or delay

FULL DISPATCH

SUZHOU, China and MÖLNDAL, Sweden, Oct. 7, 2026 /PRNewswire/ -- Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") announced the successful submission of a Phase Ⅰ Clinical Trial Application (CTA) in EU for RBD3133, a...

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

CONTEXTChina

AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

2 SOURCES CONFIRMED

№ 01prnewswireprnewswire.com · CONFIRMING2026-10-08 02:57 UTCOPEN RECEIPT →

№ 02prnewswireprnewswire.com · PRIMARY2026-10-08 01:41 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

→CORRELATIONshares China
Analysis: Is China learning to live without Iranian oil?2026-10-08 01:44 UTC

→CORRELATIONshares China
China’s Export Controls on Japan: Salami-Slicing or Strategic Signalling?2026-10-07 21:25 UTC

→CORRELATIONshares China
Bank of America sees Asia FX split as $100 oil meets chip boom2026-10-08 00:17 UTC

→CORRELATIONshares China
Malaysian Chip Firm SQAI Said to Plan $73 Million IPO in Early 20272026-10-08 01:36 UTC

←CORRELATIONshares China
Hong Kong’s third-quarter GDP grows, but external risks persist: Paul Chan2026-10-07 10:00 UTC

←CORRELATIONshares Healthcare
/C O R R E C T I O N -- Privo Technologies/2026-10-07 16:31 UTC

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.